Skip to main content
Erschienen in: Journal of Neurology 8/2011

01.08.2011 | Original Communication

Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease

verfasst von: Moeko Noguchi-Shinohara, Tsuyoshi Hamaguchi, Ichiro Nozaki, Kenji Sakai, Masahito Yamada

Erschienen in: Journal of Neurology | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Total tau protein (t-tau) levels in cerebrospinal fluid (CSF) (CSF-tau) are markedly elevated in patients with Creutzfeldt-Jakob disease (CJD). Some CSF-tau may leak into the blood. We evaluated t-tau levels in serum (serum-tau) as a possible marker for the differential diagnosis of CJD from Alzheimer’s disease (AD) and other rapidly progressive dementias (RPD). Serum- and CSF-tau levels were determined in patients with sporadic CJD (n = 12), AD (n = 10) and RPD but no CJD (non-CJD–RPD; n = 9) who showed RPD fulfilling the World Health Organization (WHO) criteria for possible CJD at onset and had a final diagnosis other than CJD. We also analyzed serum-tau levels in healthy volunteers as a control group (n = 10). Serum- as well as CSF-tau levels were significantly elevated in CJD group compared to those in AD, non-CJD–RPD and healthy control groups. Serum-tau would be a simple and useful marker to distinguish CJD from AD and non-CJD–RPD, requiring further large study to confirm this.
Literatur
1.
Zurück zum Zitat Kapaki E, Kilidireas K, Paraskevas GP et al (2001) Highly increased CSF tau protein and decreased β-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer’s disease? J Neurol Neurosurg Psychiatry 71:401–403PubMedCrossRef Kapaki E, Kilidireas K, Paraskevas GP et al (2001) Highly increased CSF tau protein and decreased β-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer’s disease? J Neurol Neurosurg Psychiatry 71:401–403PubMedCrossRef
2.
Zurück zum Zitat Reiber H (2001) Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310:173–186PubMedCrossRef Reiber H (2001) Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310:173–186PubMedCrossRef
3.
Zurück zum Zitat Van Everbroeck B, Dobbeleir I, De Waele M et al (2004) Differential diagnosis of 201 possible Creutzfeldt-Jakob disease patients. J Neurol 251:298–304PubMedCrossRef Van Everbroeck B, Dobbeleir I, De Waele M et al (2004) Differential diagnosis of 201 possible Creutzfeldt-Jakob disease patients. J Neurol 251:298–304PubMedCrossRef
4.
Zurück zum Zitat Brown P, Gibbs CJ, Rodgers-Johnson P et al (1994) Human spongiform encephalopathy: the national institutes of health series of 300 cases of experimentally transmitted disease. Ann Neurol 35:513–529PubMedCrossRef Brown P, Gibbs CJ, Rodgers-Johnson P et al (1994) Human spongiform encephalopathy: the national institutes of health series of 300 cases of experimentally transmitted disease. Ann Neurol 35:513–529PubMedCrossRef
5.
Zurück zum Zitat Poser S, Mollenhauer B, Krauß A et al (1999) How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain 122:2345–2351PubMedCrossRef Poser S, Mollenhauer B, Krauß A et al (1999) How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain 122:2345–2351PubMedCrossRef
6.
Zurück zum Zitat Will RG, Matthews WB (1984) A retrospective study of Creutzfeldt-Jakob disease in England and Wales 1970–79. I: Clinical features. J Neurol Neurosurg Psychiatry 47:134–140PubMedCrossRef Will RG, Matthews WB (1984) A retrospective study of Creutzfeldt-Jakob disease in England and Wales 1970–79. I: Clinical features. J Neurol Neurosurg Psychiatry 47:134–140PubMedCrossRef
7.
Zurück zum Zitat Tschampa HJ, Neumann M, Zerr I et al (2001) Patients with Alzheimer’s disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 71:33–39PubMedCrossRef Tschampa HJ, Neumann M, Zerr I et al (2001) Patients with Alzheimer’s disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 71:33–39PubMedCrossRef
8.
Zurück zum Zitat Hamaguchi T, Kitamoto T, Sato T et al (2005) Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. Neurology 64:643–648PubMedCrossRef Hamaguchi T, Kitamoto T, Sato T et al (2005) Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. Neurology 64:643–648PubMedCrossRef
9.
Zurück zum Zitat Gelpi E, Heinzi H, Hoftberger R et al (2008) Creutzfeldt-Jakob disease in Austria: an autopsy-controlled study. Neuroepidemiology 30:215–221PubMedCrossRef Gelpi E, Heinzi H, Hoftberger R et al (2008) Creutzfeldt-Jakob disease in Austria: an autopsy-controlled study. Neuroepidemiology 30:215–221PubMedCrossRef
11.
Zurück zum Zitat Parchi P, Giese A, Capellari S et al (1999) Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46:224–233PubMedCrossRef Parchi P, Giese A, Capellari S et al (1999) Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46:224–233PubMedCrossRef
12.
Zurück zum Zitat McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 34:939–944PubMed McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 34:939–944PubMed
13.
Zurück zum Zitat Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43:2412–2414PubMed Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43:2412–2414PubMed
14.
Zurück zum Zitat Hughes CP, Berg L, Danziger WL et al (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572PubMedCrossRef Hughes CP, Berg L, Danziger WL et al (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572PubMedCrossRef
15.
Zurück zum Zitat Folstein M, Folstein S, McHugh P (1975) ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef Folstein M, Folstein S, McHugh P (1975) ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef
16.
Zurück zum Zitat Tibbling G (1977) Principles of albumin and IgG analyses in neurological disorder. I. Establishment of reference value. Scand J Clin Lab Invest 37:385–390PubMed Tibbling G (1977) Principles of albumin and IgG analyses in neurological disorder. I. Establishment of reference value. Scand J Clin Lab Invest 37:385–390PubMed
17.
Zurück zum Zitat Kosik KS, Finch EA (1987) MAP2 and Tau segregate into dendritic and axonal domains after the elaboration of morphologically distinct neuritis: an immunocytochemical study of cultured rat cerebrum. J Neurosci 7:3142–3153PubMed Kosik KS, Finch EA (1987) MAP2 and Tau segregate into dendritic and axonal domains after the elaboration of morphologically distinct neuritis: an immunocytochemical study of cultured rat cerebrum. J Neurosci 7:3142–3153PubMed
18.
Zurück zum Zitat Wunderlich MT, Lins H, Skalej M et al (2006) Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin Neurol Neurosurg 108:558–563PubMedCrossRef Wunderlich MT, Lins H, Skalej M et al (2006) Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin Neurol Neurosurg 108:558–563PubMedCrossRef
19.
Zurück zum Zitat Sjögren M, Vanderstichele H, Ågren H et al (2001) Tau and Aβ42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin Chem 47:1776–1781PubMed Sjögren M, Vanderstichele H, Ågren H et al (2001) Tau and Aβ42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin Chem 47:1776–1781PubMed
20.
Zurück zum Zitat Satoh K, Nakaoke R, Nishiura Y et al (2010) Early detection of sporadic CJD by diffusion-weighted MRI before the onset of symptoms. J Neurol Neurosurg Psychiatry (in press) Satoh K, Nakaoke R, Nishiura Y et al (2010) Early detection of sporadic CJD by diffusion-weighted MRI before the onset of symptoms. J Neurol Neurosurg Psychiatry (in press)
21.
Zurück zum Zitat Hamaguchi T, Noguchi-Shinohara M, Nozaki I et al (2009) Medical procedures and risk for sporadic Creutzfeldt-Jakob disease, Japan, 1999–2008. Emerg Infect Dis 15:265–271PubMedCrossRef Hamaguchi T, Noguchi-Shinohara M, Nozaki I et al (2009) Medical procedures and risk for sporadic Creutzfeldt-Jakob disease, Japan, 1999–2008. Emerg Infect Dis 15:265–271PubMedCrossRef
22.
Zurück zum Zitat Nozaki I, Hamaguchi T, Sanjo N et al (2010) Prospective 10-year surveillance of human prion diseases in Japan. Brain 133:3043–3057PubMedCrossRef Nozaki I, Hamaguchi T, Sanjo N et al (2010) Prospective 10-year surveillance of human prion diseases in Japan. Brain 133:3043–3057PubMedCrossRef
23.
Zurück zum Zitat Heinemann H, Krasnianski A, Meissner B et al (2007) Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance. Brain 130:1350–1359PubMedCrossRef Heinemann H, Krasnianski A, Meissner B et al (2007) Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance. Brain 130:1350–1359PubMedCrossRef
Metadaten
Titel
Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease
verfasst von
Moeko Noguchi-Shinohara
Tsuyoshi Hamaguchi
Ichiro Nozaki
Kenji Sakai
Masahito Yamada
Publikationsdatum
01.08.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 8/2011
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-011-5960-x

Weitere Artikel der Ausgabe 8/2011

Journal of Neurology 8/2011 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.